|
1
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Giaquinto AN, Miller KD, Tossas KY, Winn
RA, Jemal A and Siegel RL: Cancer statistics for African
American/Black People 2022. CA Cancer J Clin. 72:202–229. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burnett-Hartman AN, Lee JK, Demb J and
Gupta S: An update on the epidemiology, molecular characterization,
diagnosis, and screening strategies for early-onset colorectal
cancer. Gastroenterology. 160:1041–1049. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A Review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bien J and Lin A: A review of the
diagnosis and treatment of metastatic colorectal cancer. JAMA.
325:2404–2405. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Portella L, Bello AM and Scala S: CXCL12
Signaling in the tumor microenvironment. Adv Exp Med Biol.
1302:51–70. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smit MJ, Schlecht-Louf G, Neves M, van den
Bor J, Penela P, Siderius M, Bachelerie F and Mayor F Jr: The
CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling,
crosstalk, and therapeutic targeting. Annu Rev Pharmacol Toxicol.
61:541–563. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Britton C, Poznansky MC and Reeves P:
Polyfunctionality of the CXCR4/CXCL12 axis in health and disease:
Implications for therapeutic interventions in cancer and
immune-mediated diseases. FASEB J. 35:e212602021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huynh C, Dingemanse J, Meyer Zu
Schwabedissen HE and Sidharta PN: Relevance of the
CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological
conditions. Pharmacol Res. 161:1050922020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janssens R, Struyf S and Proost P: The
unique structural and functional features of CXCL12. Cell Mol
Immunol. 15:299–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lopez-Gil JC, Martin-Hijano L, Hermann PC
and Sainz B Jr: The CXCL12 crossroads in cancer stem cells and
their niche. Cancers (Basel). 13:4692021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mortezaee K: CXCL12/CXCR4 axis in the
microenvironment of solid tumors: A critical mediator of
metastasis. Life Sci. 249:1175342020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y, Riese DJ II and Shen J: The Role of
the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol.
11:5746672020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mezzapelle R, Leo M, Caprioglio F, Colley
LS, Lamarca A, Sabatino L, Colantuoni V, Crippa MP and Bianchi ME:
CXCR4/CXCL12 activities in the tumor microenvironment and
implications for tumor immunotherapy. Cancers (Basel). 14:23142022.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goita AA and Guenot D: Colorectal cancer:
The contribution of CXCL12 and its receptors CXCR4 and CXCR7.
Cancers (Basel). 14:18102022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khare T, Bissonnette M and Khare S:
CXCL12-CXCR4/CXCR7 axis in colorectal cancer: Therapeutic target in
preclinical and clinical studies. Int J Mol Sci. 22:73712021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshitake N, Fukui H, Yamagishi H,
Sekikawa A, Fujii S, Tomita S, Ichikawa K, Imura J, Hiraishi H and
Fujimori T: Expression of SDF-1 alpha and nuclear CXCR4 predicts
lymph node metastasis in colorectal cancer. Br J Cancer.
98:1682–1689. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akishima-Fukasawa Y, Nakanishi Y, Ino Y,
Moriya Y, Kanai Y and Hirohashi S: Prognostic significance of
CXCL12 expression in patients with colorectal carcinoma. Am J Clin
Pathol. 132:202–210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saigusa S, Toiyama Y, Tanaka K, Yokoe T,
Okugawa Y, Kawamoto A, Yasuda H, Inoue Y, Miki C and Kusunoki M:
Stromal CXCR4 and CXCL12 expression is associated with distant
recurrence and poor prognosis in rectal cancer after
chemoradiotherapy. Ann Surg Oncol. 17:2051–2058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakai N, Yoshidome H, Shida T, Kimura F,
Shimizu H, Ohtsuka M, Takeuchi D, Sakakibara M and Miyazaki M:
CXCR4/CXCL12 expression profile is associated with tumor
microenvironment and clinical outcome of liver metastases of
colorectal cancer. Clin Exp Metastasis. 29:101–110. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yopp AC, Shia J, Butte JM, Allen PJ, Fong
Y, Jarnagin WR, DeMatteo RP and D'Angelica MI: CXCR4 expression
predicts patient outcome and recurrence patterns after hepatic
resection for colorectal liver metastases. Ann Surg Oncol. 19
(Suppl 3):S339–S346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
D'Alterio C, Avallone A, Tatangelo F,
Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno
C, Bianco F, et al: A prognostic model comprising pT stage, N
status, and the chemokine receptors CXCR4 and CXCR7 powerfully
predicts outcome in neoadjuvant resistant rectal cancer patients.
Int J Cancer. 135:379–390. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amara S, Chaar I, Khiari M, Ounissi D,
Weslati M, Boughriba R, Hmida AB and Bouraoui S: Stromal cell
derived factor-1 and CXCR4 expression in colorectal cancer promote
liver metastasis. Cancer Biomark. 15:869–879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
D'Alterio C, Nasti G, Polimeno M, Ottaiano
A, Conson M, Circelli L, Botti G, Scognamiglio G, Santagata S, De
Divitiis C, et al: CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in
colorectal cancer liver metastases from neoadjuvant-treated
patients. Oncoimmunology. 5:e12543132016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Cuba EM, de Hingh IH, Sluiter NR,
Kwakman R, Coupé VM, Beliën JA, Verwaal VJ, Meijerink WJ, Delis-van
Diemen PM, Bonjer HJ, et al: Angiogenesis-Related markers and
prognosis after cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy for metastatic colorectal cancer. Ann
Surg Oncol. 23:1601–1608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stanisavljevic L, Assmus J, Storli KE, Leh
SM, Dahl O and Myklebust MP: CXCR4, CXCL12 and the relative
CXCL12-CXCR4 expression as prognostic factors in colon cancer.
Tumour Biol. 37:7441–7452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mitchell A, Hasanali SL, Morera DS, Baskar
R, Wang X, Khan R, Talukder A, Li CS, Manoharan M, Jordan AR, et
al: A chemokine/chemokine receptor signature potentially predicts
clinical outcome in colorectal cancer patients. Cancer Biomark.
26:291–301. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lalos A, Tulek A, Tosti N, Mechera R,
Wilhelm A, Soysal S, Daester S, Kancherla V, Weixler B, Spagnoli
GC, et al: Prognostic significance of CD8+ T-cells density in stage
III colorectal cancer depends on SDF-1 expression. Sci Rep.
11:7752021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim S, Yeo MK, Kim JS, Kim JY and Kim KH:
Elevated CXCL12 in the plasma membrane of locally advanced rectal
cancer after neoadjuvant chemoradiotherapy: A potential prognostic
marker. J Cancer. 13:162–173. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Page MJ, Moher D, Bossuyt PM, Boutron I,
Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: PRISMA 2020 explanation and elaboration: Updated
guidance and exemplars for reporting systematic reviews. BMJ.
372:n1602021. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372:n712021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Higgins J, Thomas J, Chandler J, Cumpston
M, Li T, Page MJ and Welch VA: Cochrane Handbook for Systematic
Reviews of Interventions version 6.2. The Cochrane Collaboration.
www.training.cochrane.org/handbook2021
|
|
34
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Tugwell P and Losos M: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp2010
|
|
35
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Patsopoulos NA, Evangelou E and Ioannidis
JP: Sensitivity of between-study heterogeneity in meta-analysis:
Proposed metrics and empirical evaluation. Int J Epidemiol.
37:1148–1157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Samarendra H, Jones K, Petrinic T, Silva
MA, Reddy S, Soonawalla Z and Gordon-Weeks A: A meta-analysis of
CXCL12 expression for cancer prognosis. Br J Cancer. 117:124–135.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li YP, Pang J, Gao S, Bai PY, Wang WD,
Kong P and Cui Y: Role of CXCR4 and SDF1 as prognostic factors for
survival and the association with clinicopathology in colorectal
cancer: A systematic meta-analysis. Tumour Biol.
39:10104283177062062017.PubMed/NCBI
|
|
40
|
Brand S, Dambacher J, Beigel F, Olszak T,
Diebold J, Otte JM, Göke B and Eichhorst ST: CXCR4 and CXCL12 are
inversely expressed in colorectal cancer cells and modulate cancer
cell migration, invasion and MMP-9 activation. Exp Cell Res.
310:117–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma J, Su H, Yu B, Guo T, Gong Z, Qi J,
Zhao X and Du J: CXCL12 gene silencing down-regulates metastatic
potential via blockage of MAPK/PI3K/AP-1 signaling pathway in colon
cancer. Clin Transl Oncol. 20:1035–1045. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu X, Wang D, Wang X, Sun S, Zhang Y, Wang
S, Miao R, Xu X and Qu X: CXCL12/CXCR4 promotes inflammation-driven
colorectal cancer progression through activation of RhoA signaling
by sponging miR-133a-3p. J Exp Clin Cancer Res. 38:322019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang D, Jiao C, Zhu Y, Liang D, Zao M,
Meng X, Gao J, He Y, Liu W, Hou J, et al: Activation of
CXCL12/CXCR4 renders colorectal cancer cells less sensitive to
radiotherapy via up-regulating the expression of survivin. Exp Biol
Med (Maywood). 242:429–435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fang Y, Zheng T and Zhang C: Prognostic
Role of the C-Reactive Protein/Albumin ratio in patients with
gynecological cancers: A meta-analysis. Front Oncol. 11:7371552021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim MS, Chun SW, Dho YS, Seo Y, Lee JH,
Won JK, Kim JW, Park CK, Park SH and Kim YH: Histopathological
predictors of progression-free survival in atypical meningioma: A
single-center retrospective cohort and meta-analysis. Brain Tumor
Pathol. 39:99–110. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Peng Q, Liu L, Li T, Lei C and Wan H:
Prognostic impact of prognostic nutritional index on renal cell
carcinoma: A meta-analysis of 7,629 patients. PLoS One.
17:e02651192022. View Article : Google Scholar : PubMed/NCBI
|
